-
Most Recent
Search Results
240 results for abv
AbbVie (ABBV) a Buy on Strong Quant Score
Currently, AbbVie Inc (NYSE:ABBV) has a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. ABBV has maintained this…
AbbVie (ABBV) a Buy on Robust Quant Score
AbbVie Inc (NYSE:ABBV) is a $147.1 billion in market value member of the Biotechnology GICS industry group where the stock’s current Portfolio Grader score places…
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
AbbVie (ABBV) a Strong Buy at $117.98
At $117.98, AbbVie (ABBV) a Strong Buy based on the latest SEC filings, and comparative pricing of its shares.
AbbVie Inc: ABBV Stock Is a Prescription for Profits
Investors and traders should be positioning themselves in AbbVie stock. This trade on ABBV will help you limit earnings volatility while allowing you to enjoy…
AbbVie Inc (ABBV) Is About to Steamroll the Competition
Good news for AbbVie (ABBV) shareholders: The pharmaceutical company just entered the Hepatitis C. market, while reinforcing its position in the psoriasis area. Given ABBV’s…
Trade of the Day: AbbVie Inc. (NYSE:ABBV)
AbbVie has a great opportunity for growth in developing and commercialize BioArctic’s treatment platform for neurodegenerative diseases.
Hold Recommendation for AbbVie (ABBV) Stock Kept
Currently, AbbVie Inc (NYSE:ABBV) has a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing approach. This represents no change…
ABBV Stock Slips as AbbVie Faces Opioid Lawsuits
AbbVie’s quarterly results were roughly in line with Wall Street’s expectations, but ABBV stock still slipped in early trading.
AbbVie Inc (ABBV) Earnings: 12 Things to Know
AbbVie (ABBV) has released its earnings report for the third quarter of 2017 and ‘InvestorPlace’ has a few things to know about it.
Superior Earnings Momentum Keeps AbbVie (ABBV) a Buy
AbbVie Inc (NYSE:ABBV) is one of 345 companies within the Biotechnology GICS industry group, which is in turn part of the 782 company GICS Health…
JD.com Stock Should Be Able to Soar Above $50
JD stock has been troubled for several years now, but the long-term growth outlook is steadily improving – thanks to global retail expansion, a tailwind…
Biggest Movers in Services Stocks Now – ARE CCO AVB AIV
Services stocks finished down broadly on Wall Street on Monday, with the sector seeing an overall decline of 0.5%.
AbbVie Inc (ABBV) Has More Blockbusters on the Horizon
AbbVie (ABBV) isn’t just resting on the success of Humira; this major pharmaceutical firm is building for a long, strong future.
ABBV: AbbVie Beats Street on Soaring Humira Sales
Pharmaceutical-maker AbbVie posted first-quarter sales that beat estimates on surging sales of its Humira drug, sending ABBV stock higher.
AbbVie Earnings: 5 Things for ABBV Stock Investors to Note
AbbVie (ABBV) earnings for the biopharmaceutical company’s third quarter of 2019 have ABBV stock up Friday on an EPS and revenue beat.
Earnings Momentum Analytics Power AbbVie (ABBV) to Strong Buy
The current recommendation of Strong Buy for AbbVie Inc (NYSE:ABBV) has been derived by using Louis Navellier’s Portfolio Grader stock evaluator, which incorporates his investing…
Why AbbVie Inc Was a Named Top Dividend Stock (ABBV)
AbbVie Inc has been named to the Dividend Channel’s SAFE dividend list based upon these key metrics
AbbVie (ABBV) a Strong Buy on Best-in-Class Quant Score
AbbVie Inc (NYSE:ABBV) is a constituent of the 350 company Biotechnology GICS industry group, which is a segment of the 782 company GICS Health Care…
AbbVie (ABBV) a Strong Buy on Top-End Earnings Momentum
Portfolio Grader currently ranks AbbVie Inc (NYSE:ABBV) a Strong Buy. The methods for fundamental and quantitative metrics used in this analytical tool, developed by Louis…
AbbVie Earnings: ABBV Stock Falters on Q4 Miss
AbbVie earnings for the fourth quarter of 2018 saw ABBV stock falling today after reporting an earnings per share and revenue miss.
AbbVie Earnings: ABBV Stock Pops on Q2 Beat
AbbVie earnings for the second quarter of 2019 have ABBV stock up on Friday thanks to it beating EPS and revenue estimates.
10 Best “Strong Buy” Stocks — ABG ABT ACHC and more
This week, these ten stocks, all currently earning A’s (“strong buy”) on Portfolio Grader, have the best year-to-date performance. Since the beginning of the year,…
7 – 10 of 240 results
